Endoscopic Procedure Outperforms Oral Weight Loss Pill in New Study

MILAN, Italy – May 14, 2026 – A groundbreaking study has found that a minimally invasive endoscopic procedure leads to significantly greater short-term weight loss than a widely used oral medication, providing critical new data for patients and clinicians navigating the complex landscape of obesity treatment.

The findings, presented at the ESGE Days 2026 conference, revealed that Endoscopic Sleeve Gastroplasty (ESG) resulted in nearly 50% more weight loss at six months compared to oral semaglutide, a popular GLP-1 receptor agonist. This research offers one of the first direct, real-world comparisons between a one-time procedure and a daily pill, addressing a pivotal question in modern weight management.

A Head-to-Head Comparison

The retrospective study analyzed outcomes for 150 adults with obesity in a routine clinical setting. After six months, patients who underwent Endoscopic Sleeve Gastroplasty—a procedure that reduces the stomach's volume using an endoscope passed through the mouth—achieved an average total body weight loss of 12.7%. In contrast, patients taking the 14mg daily dose of oral semaglutide lost an average of 8.7%.

This 4.0% difference was statistically significant (p=0.0001) and held firm even after researchers adjusted for baseline differences in age, sex, body mass index (BMI), and diabetes status.

The study's lead author, Dr. Nitin G. Jagtap, highlighted the real-world relevance of the comparison. "In real-world practice, patients often ask whether they should choose a procedure or a medicine, but there has been very little comparative data to guide that decision," he stated. "We focused on oral semaglutide because it was the most commonly available option during the study period, so this reflects a real-world clinical decision, not an artificial comparison."

Beyond the average weight loss, the procedure also proved more effective at helping patients reach clinically meaningful milestones. A striking 70% of patients in the ESG group lost at least 10% of their total body weight, a common benchmark for significant health improvements. Only 43% of the semaglutide group reached that goal. The gap was even wider for more substantial weight loss, with 36% of ESG patients achieving at least 15% weight loss compared to just 7% in the medication group.

Importantly, the increased efficacy did not come with a higher risk profile in the short term. The study reported that adverse event rates were comparable between the two groups, consisting mainly of mild gastrointestinal symptoms. No serious complications or deaths were reported.

Durability and the Long-Term View

While the new study focuses on a six-month window, its findings tap into a broader conversation among obesity specialists about the long-term sustainability of different treatments. GLP-1 medications like semaglutide have been hailed as revolutionary, but their effectiveness is contingent on continuous, long-term use. Experts note that when patients stop taking the medication—due to cost, side effects, insurance issues, or personal choice—weight regain is a common and significant challenge.

ESG, by contrast, creates a durable anatomical change. The procedure involves placing sutures in the stomach to reduce its size by about 70-80%, which physically restricts food intake and promotes earlier feelings of fullness. Existing long-term data on ESG suggests this effect is lasting. Separate studies have shown that patients can maintain an average total body weight loss of around 16% at five years post-procedure.

"A daily oral therapy requires sustained commitment, whereas ESG is a one-time intervention associated with more rapid weight loss," Dr. Jagtap explained.

Furthermore, some experts point to differences in the quality of weight lost. Research has indicated that a substantial portion of weight lost with GLP-1 agonists, sometimes as high as 30-40%, can come from lean muscle mass. In contrast, the mechanical nature of ESG appears to be more "muscle-sparing," with studies suggesting lean mass accounts for only about 10-15% of the total weight lost. Preserving muscle is critical for maintaining metabolic health and physical function during weight loss.

The Deciding Factors: Cost, Access, and Personalization

Despite the strong efficacy shown by ESG, the choice of treatment is rarely simple. Cost and accessibility remain significant hurdles. A five-year analysis found ESG to be cost-saving compared to semaglutide for class II obesity, largely due to the high, recurring cost of the medication and higher patient dropout rates. For semaglutide to be as cost-effective as ESG, its annual price would need to drop from over $13,000 to under $4,000.

However, the financial calculus for patients is different. The high upfront cost of ESG can be a barrier, and insurance coverage for endoscopic bariatric therapies remains inconsistent. Conversely, while the monthly cost of oral semaglutide is high, insurance plans—particularly those for patients with type 2 diabetes—can bring the co-pay down to a manageable level, though coverage for weight loss alone is often denied.

This complex web of factors underscores the central message from Dr. Jagtap and other experts: treatment must be individualized. "These approaches should be viewed as complementary," he advised, emphasizing the need to consider patient preference, the ability to adhere to a daily medication regimen, and long-term goals.

An Evolving Treatment Landscape

The ESGE Days study arrives at a pivotal moment for obesity care. The year 2026 is being called the "year of the orals," as the market for GLP-1 agonists explodes with new, more convenient options. Novo Nordisk's oral version of Wegovy received FDA approval for weight loss in late 2025, and Eli Lilly's competing oral drug, orforglipron, is expected to launch this year. This shift away from injectables is poised to dramatically expand the use of pharmacological obesity treatments.

In this context, the new data on ESG serves as a crucial reminder of the powerful and enduring role of procedural interventions. It suggests that even as pharmaceutical options become more accessible and varied, minimally invasive procedures will remain a vital, and for many patients, a more effective tool in the fight against obesity.

"The future of care lies in personalised treatment selection – matching the right approach to the right patient," Dr. Jagtap concluded. This study provides a vital piece of evidence to help make that selection more informed than ever before.